A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

This trial is testing a drug called sutetinib maleate capsule for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has an uncommon EGFR gene mutation. EGFR mutations tell cancer cells to grow rapidly, and targeted drugs like sutetinib aim to block this signal. **You may be eligible if...** - You are 18 or older - You have confirmed locally advanced or metastatic NSCLC with an uncommon EGFR mutation - You have never received an EGFR-targeting drug (Cohort 1) or have not received a second-generation EGFR drug (Cohort 2) - You are in good health (ECOG 0–2) - You have at least one measurable tumor and a life expectancy over 3 months - Your blood, liver, kidney, and clotting function are adequate **You may NOT be eligible if...** - You received chemotherapy, radiation, or immunotherapy within the past 3–4 weeks - You are currently taking medications that strongly affect a liver enzyme called CYP3A4 - You had major surgery in the past 3 weeks and haven't fully recovered - You are pregnant, breastfeeding, or not using adequate contraception Talk to your doctor to see if this trial is right for you.